Optiver Holding B.V. Takes $757,000 Position in Genmab A/S (NASDAQ:GMAB)

Optiver Holding B.V. purchased a new position in Genmab A/S (NASDAQ:GMAB - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 36,260 shares of the company's stock, valued at approximately $757,000.

Other large investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC boosted its holdings in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares during the period. Barclays PLC lifted its holdings in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after buying an additional 2,285 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on GMAB shares. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, Truist Financial dropped their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $39.17.

Genmab A/S Price Performance

GMAB opened at $20.63 on Tuesday. The company's 50 day simple moving average is $20.45 and its two-hundred day simple moving average is $21.00. Genmab A/S has a 1-year low of $17.24 and a 1-year high of $30.41. The firm has a market capitalization of $13.66 billion, a price-to-earnings ratio of 11.86, a price-to-earnings-growth ratio of 2.65 and a beta of 1.07.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.